Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 5/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | PLEKHA1 | Q9HB21 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 7/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122210 | 1.00 | AKT1 (0.49) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| SCHEMBL18043741 | 1.00 | AKT1 (0.49) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL26921279 | 0.98 | AKT1 (0.51) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL26923029 | 0.98 | AKT1 (0.51) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| SCHEMBL19934375 | 0.81 | KMT2A (0.42) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| SCHEMBL20653616 | 0.81 | AKT1 (0.40) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| SCHEMBL2757622 | 0.78 | IDO1 (0.39) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| SCHEMBL14592141 | 0.76 | AKT1 (0.55) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| SCHEMBL122211 | 0.76 | AKT1 (0.55) | AKT1BTKPLEKHA1POLBALDH1A1 | |
| SCHEMBL150406 | 0.76 | AKT1 (0.55) | AKT1BTKPLEKHA1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340758-A1 | PET PROBES OF RADIOFLUORINATED CARBOXIMIDAMIDES FOR IDO-TARGETED IMAGING | H LEE MOFFITT CANCER CT & RES (US) | 2017-11-30 | — | — | US | claimed |
| WO-2016040458-A2 | PET PROBES OF RADIOFLUORINATED CARBOXIMIDAMIDES FOR IDO-TARGETED IMAGING | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-3389783-B1 | NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3389783-B1 | NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE HOLDINGS CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | disclosed |
| EP-2911669-B1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | UNIV CHICAGO (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4288433-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-110139857-B | Sulfoximine, sulfoximinamide, sulfodiimine, and diimine sulfonamide compounds as indoleamine 2,3-dioxygenase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-107954999-B | Oxadiazole ring-containing compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-8034953-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2315756-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION | 2010-01-21 | — | — | US | disclosed |
| WO-2010005958-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-1879573-A4 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORP (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1879573-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006122150-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PEBP1, PLTP | AKT1 2341/4885BTK 4405/4885PLEKHA1 505/4885 |
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | AKT1 2573/4885BTK 3274/4885PLEKHA1 2954/4885 |
| US-20240158385-A1 | NOVEL COMPOUNDS | KCNK3, KCNA4, KCNK13 | AKT1 1636/4885BTK 1110/4885PLEKHA1 3622/4885 |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | AKT1 2573/4885BTK 3274/4885PLEKHA1 2954/4885 |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | AKT1 2938/4885BTK 3338/4885PLEKHA1 4565/4885 |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | AKT1 2938/4885BTK 3338/4885PLEKHA1 4565/4885 |
| US-20170340758-A1 | PET PROBES OF RADIOFLUORINATED CARBOXIMIDAMIDES FOR IDO-TARGETED IMAGING | IDO1, IDO2, IDH1 | AKT1 4009/4885BTK 3603/4885PLEKHA1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.